Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why Regeneron (REGN) Stock Is Down Today

September 23, 2025 at 15:26 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

REGN Cover Image

What Happened?

Shares of biotech company Regeneron (NASDAQ: REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its blockbuster eye drug, EYLEA.

A judge dismissed Regeneron's request for an injunction against Sandoz, which plans to launch its own version of the treatment for eye disorders like macular degeneration. This decision raised investor concerns about future competition for EYLEA, a major source of revenue for the company. The negative development overshadowed recent positive news about another drug, Dupixent, receiving a favorable opinion in Europe for a new use. The setback for EYLEA added to existing worries, as the company's revenue growth had already slowed over the previous two years and its operating margins had declined.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Regeneron’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 4 months ago when the stock dropped 19% on the news that the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic Obstructive Pulmonary Disease (COPD).

While one trial met its primary endpoint, the other missed, raising concerns about the drug's future and delaying its potential market entry. This setback, likely spooked investors and contributed to the significant decline.

Regeneron is down 20.5% since the beginning of the year, and at $568.50 per share, it is trading 47.9% below its 52-week high of $1,092 from September 2024. Investors who bought $1,000 worth of Regeneron’s shares 5 years ago would now be looking at an investment worth $1,006.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article